Skip to main content
Top
Published in: Journal of Cancer Research and Clinical Oncology 4/2024

Open Access 01-04-2024 | Gastric Cancer | Research

UBE2L3 expression in human gastric cancer and its clinical significance

Authors: Xiaoxia Zhang, Yujie Wei, Fanqi Wu, Mei Li, Cong Han, Chengdong Huo, Zhi Li, Futian Tang, Wenting He, Yang Zhao, Yumin Li

Published in: Journal of Cancer Research and Clinical Oncology | Issue 4/2024

Login to get access

Abstract

Purpose

Gastric cancer (GC) is prevalent as one of the most common malignant tumors globally, with a particularly high incidence in China. The role of UBE2L3 in the initiation and progression of various cancers has been well documented, but its specific significance in GC is not yet fully elucidated. The objective of this study is to examine the expression and importance of UBE2L3 in human gastric cancer tissues.

Methods

Immunohistochemical staining and survival analysis were conducted on 125 cases of GC. Western blot and quantitative real-time polymerase chain reaction (qRT-PCR) were employed to assess the expression of UBE2L3 in GC cell lines. Cell lines with UBE2L3 knockdown and overexpression were cultured through lentivirus transfection and subsequently assessed using Western blot analysis. The involvement of UBE2L3 in the proliferation, invasion, and apoptosis of GC cells was confirmed through in vitro experiments, and its capacity to facilitate tumor growth was also validated in in vivo studies.

Results

The up-regulation of UBE2L3 expression was observed in GC, and its high expression was found to be significantly associated with the degree of differentiation (χ2 = 6.153, P = 0.0131), TNM stage (χ2 = 6.216, P = 0.0447), and poor overall survival. In vitro, UBE2L3 has been shown to enhance functions in GC cell lines, such as promoting proliferation and invasion, and inhibiting apoptosis. In vivo experiments have validated the role of UBE2L3 in promoting tumor growth.

Conclusions

The findings of our study demonstrate the significant involvement of UBE2L3 in the pathogenesis and advancement of gastric cancer, suggesting its potential as a therapeutic target.
Appendix
Available only for authorised users
Literature
go back to reference Al-Batran S-E, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, Kopp H-G, Mayer F, Haag GM, Luley K (2019) Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. The Lancet 393(10184):1948–1957CrossRef Al-Batran S-E, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, Kopp H-G, Mayer F, Haag GM, Luley K (2019) Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. The Lancet 393(10184):1948–1957CrossRef
go back to reference Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424CrossRefPubMed Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424CrossRefPubMed
go back to reference Cats A, Jansen EP, van Grieken NC, Sikorska K, Lind P, Nordsmark M, Kranenbarg EM-K, Boot H, Trip AK, Swellengrebel HM (2018) Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. Lancet Oncol 19(5):616–628CrossRefPubMed Cats A, Jansen EP, van Grieken NC, Sikorska K, Lind P, Nordsmark M, Kranenbarg EM-K, Boot H, Trip AK, Swellengrebel HM (2018) Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. Lancet Oncol 19(5):616–628CrossRefPubMed
go back to reference Clague MJ, Heride C, Urbé S (2015) The demographics of the ubiquitin system. Trends Cell Biol 25(7):417–426CrossRefPubMed Clague MJ, Heride C, Urbé S (2015) The demographics of the ubiquitin system. Trends Cell Biol 25(7):417–426CrossRefPubMed
go back to reference Cui Z, Sun S, Li J, Li J, Sha T, He J, Zuo L (2022) UBE2L3 promotes squamous cell carcinoma progression in the oral cavity and hypopharynx via activating the NF-κB signaling by increasing IκBα degradation. Cell Biol Int 46(5):806–818CrossRefPubMed Cui Z, Sun S, Li J, Li J, Sha T, He J, Zuo L (2022) UBE2L3 promotes squamous cell carcinoma progression in the oral cavity and hypopharynx via activating the NF-κB signaling by increasing IκBα degradation. Cell Biol Int 46(5):806–818CrossRefPubMed
go back to reference Ferlay J, Ervik M, Colombet M, et al. (Published 2020. Accessed September 30, 2021) Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer Ferlay J, Ervik M, Colombet M, et al. (Published 2020. Accessed September 30, 2021) Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer
go back to reference Fernandez-Jimenez N, Bilbao JR (2019) Mendelian randomization analysis of celiac GWAS reveals a blood expression signature with diagnostic potential in absence of gluten consumption. Hum Mol Genet 28(18):3037–3042CrossRefPubMedPubMedCentral Fernandez-Jimenez N, Bilbao JR (2019) Mendelian randomization analysis of celiac GWAS reveals a blood expression signature with diagnostic potential in absence of gluten consumption. Hum Mol Genet 28(18):3037–3042CrossRefPubMedPubMedCentral
go back to reference Han X, Zhang L, Chung J, Mayca Pozo F, Tran A, Seachrist DD, Jacobberger JW, Keri RA, Gilmore H, Zhang Y (2014) UbcH7 regulates 53BP1 stability and DSB repair. Proc Natl Acad Sci 111(49):17456–17461CrossRefPubMedPubMedCentral Han X, Zhang L, Chung J, Mayca Pozo F, Tran A, Seachrist DD, Jacobberger JW, Keri RA, Gilmore H, Zhang Y (2014) UbcH7 regulates 53BP1 stability and DSB repair. Proc Natl Acad Sci 111(49):17456–17461CrossRefPubMedPubMedCentral
go back to reference Heo MJ, Kang SH, Kim YS, Lee JM, Yu J, Kim HR, Lim H, Kim KM, Jung J, Jeong LS (2020) UBC12-mediated SREBP-1 neddylation worsens metastatic tumor prognosis. Int J Cancer 147(9):2550–2563CrossRefPubMed Heo MJ, Kang SH, Kim YS, Lee JM, Yu J, Kim HR, Lim H, Kim KM, Jung J, Jeong LS (2020) UBC12-mediated SREBP-1 neddylation worsens metastatic tumor prognosis. Int J Cancer 147(9):2550–2563CrossRefPubMed
go back to reference Huang P, Guo Y, Zhao Z, Ning W, Wang H, Gu C, Zhang M, Qu Y, Zhang H, Song Y (2020) UBE2T promotes glioblastoma invasion and migration via stabilizing GRP78 and regulating EMT. Aging (albany NY) 12(11):10275CrossRefPubMed Huang P, Guo Y, Zhao Z, Ning W, Wang H, Gu C, Zhang M, Qu Y, Zhang H, Song Y (2020) UBE2T promotes glioblastoma invasion and migration via stabilizing GRP78 and regulating EMT. Aging (albany NY) 12(11):10275CrossRefPubMed
go back to reference Jiang X, Ma Y, Wang T, Zhou H, Wang K, Shi W, Qin L, Guan J, Li L, Long B (2023) Targeting UBE2T potentiates gemcitabine efficacy in pancreatic cancer by regulating pyrimidine metabolism and replication stress. Gastroenterology 164(7):1232–1247CrossRefPubMed Jiang X, Ma Y, Wang T, Zhou H, Wang K, Shi W, Qin L, Guan J, Li L, Long B (2023) Targeting UBE2T potentiates gemcitabine efficacy in pancreatic cancer by regulating pyrimidine metabolism and replication stress. Gastroenterology 164(7):1232–1247CrossRefPubMed
go back to reference Kawazoe A, Fukuoka S, Nakamura Y, Kuboki Y, Wakabayashi M, Nomura S, Mikamoto Y, Shima H, Fujishiro N, Higuchi T (2020) Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial. Lancet Oncol 21(8):1057–1065CrossRefPubMed Kawazoe A, Fukuoka S, Nakamura Y, Kuboki Y, Wakabayashi M, Nomura S, Mikamoto Y, Shima H, Fujishiro N, Higuchi T (2020) Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial. Lancet Oncol 21(8):1057–1065CrossRefPubMed
go back to reference Kim T, Bae S-C, Kang C (2020) Synergistic activation of NF-κB by TNFAIP3 (A20) reduction and UBE2L3 (UBCH7) augment that synergistically elevate lupus risk. Arthritis Res Ther 22:1–10CrossRef Kim T, Bae S-C, Kang C (2020) Synergistic activation of NF-κB by TNFAIP3 (A20) reduction and UBE2L3 (UBCH7) augment that synergistically elevate lupus risk. Arthritis Res Ther 22:1–10CrossRef
go back to reference Ma X, Qi W, Yang F, Pan H (2022) UBE2L3 promotes lung adenocarcinoma invasion and metastasis through the GSK-3β/Snail signaling pathway. Am J Transl Res 14(7):4549PubMedPubMedCentral Ma X, Qi W, Yang F, Pan H (2022) UBE2L3 promotes lung adenocarcinoma invasion and metastasis through the GSK-3β/Snail signaling pathway. Am J Transl Res 14(7):4549PubMedPubMedCentral
go back to reference Marrugal Á, Ferrer I, Quintanal-Villalonga Á, Ojeda L, Pastor MD, García-Luján R, Carnero A, Paz-Ares L, Molina-Pinelo S (2023) Inhibition of HSP90 in driver oncogene-defined lung adenocarcinoma cell lines: key proteins underpinning therapeutic efficacy. Int J Mol Sci 24(18):13830CrossRefPubMedPubMedCentral Marrugal Á, Ferrer I, Quintanal-Villalonga Á, Ojeda L, Pastor MD, García-Luján R, Carnero A, Paz-Ares L, Molina-Pinelo S (2023) Inhibition of HSP90 in driver oncogene-defined lung adenocarcinoma cell lines: key proteins underpinning therapeutic efficacy. Int J Mol Sci 24(18):13830CrossRefPubMedPubMedCentral
go back to reference Mauro D, Manou-Stathopoulou S, Rivellese F, Sciacca E, Goldmann K, Tsang V, Lucey-Clayton I, Pagani S, Alam F, Pyne D, Rajakariar R, Gordon PA, Whiteford J, Bombardieri M, Pitzalis C, Lewis MJ (2023a) UBE2L3 regulates TLR7-induced B cell autoreactivity in systemic lupus erythematosus. J Autoimmun 136:103023CrossRefPubMed Mauro D, Manou-Stathopoulou S, Rivellese F, Sciacca E, Goldmann K, Tsang V, Lucey-Clayton I, Pagani S, Alam F, Pyne D, Rajakariar R, Gordon PA, Whiteford J, Bombardieri M, Pitzalis C, Lewis MJ (2023a) UBE2L3 regulates TLR7-induced B cell autoreactivity in systemic lupus erythematosus. J Autoimmun 136:103023CrossRefPubMed
go back to reference Pozo FM, Tang J, Bonk KW, Keri RA, Yao X, Zhang Y (2017) Regulatory cross-talk determines the cellular levels of 53BP1 protein, a critical factor in DNA repair. J Biol Chem 292(14):5992–6003CrossRef Pozo FM, Tang J, Bonk KW, Keri RA, Yao X, Zhang Y (2017) Regulatory cross-talk determines the cellular levels of 53BP1 protein, a critical factor in DNA repair. J Biol Chem 292(14):5992–6003CrossRef
go back to reference Qi S, Guan X, Zhang J, Yu D, Yu X, Li Q, Yin W, Cheng X-D, Zhang W, Qin J-J (2022) Targeting E2 ubiquitin-conjugating enzyme UbcH5c by small molecule inhibitor suppresses pancreatic cancer growth and metastasis. Mol Cancer 21(1):70CrossRefPubMedPubMedCentral Qi S, Guan X, Zhang J, Yu D, Yu X, Li Q, Yin W, Cheng X-D, Zhang W, Qin J-J (2022) Targeting E2 ubiquitin-conjugating enzyme UbcH5c by small molecule inhibitor suppresses pancreatic cancer growth and metastasis. Mol Cancer 21(1):70CrossRefPubMedPubMedCentral
go back to reference Sexton RE, Al Hallak MN, Diab M, Azmi AS (2020) Gastric cancer: a comprehensive review of current and future treatment strategies. Cancer Metastasis Rev 39:1179–1203CrossRefPubMedPubMedCentral Sexton RE, Al Hallak MN, Diab M, Azmi AS (2020) Gastric cancer: a comprehensive review of current and future treatment strategies. Cancer Metastasis Rev 39:1179–1203CrossRefPubMedPubMedCentral
go back to reference Shima T, Ogura M, Matsuda R, Nakamura S, Jin N, Yoshimori T, Kuma A (2023) The TMEM192-mKeima probe specifically assays lysophagy and reveals its initial steps. J Cell Biol 222(12):e202204048CrossRefPubMedPubMedCentral Shima T, Ogura M, Matsuda R, Nakamura S, Jin N, Yoshimori T, Kuma A (2023) The TMEM192-mKeima probe specifically assays lysophagy and reveals its initial steps. J Cell Biol 222(12):e202204048CrossRefPubMedPubMedCentral
go back to reference Smyth EC, Nilsson M, Grabsch HI, van Grieken NCT, Lordick F (2020) Gastric cancer. The Lancet 396(10251):635–648CrossRef Smyth EC, Nilsson M, Grabsch HI, van Grieken NCT, Lordick F (2020) Gastric cancer. The Lancet 396(10251):635–648CrossRef
go back to reference Sun J, Zhu Z, Li W, Shen M, Cao C, Sun Q, Guo Z, Liu L, Wu D (2020) UBE2T-regulated H2AX monoubiquitination induces hepatocellular carcinoma radioresistance by facilitating CHK1 activation. J Exp Clin Cancer Res 39(1):1–18CrossRef Sun J, Zhu Z, Li W, Shen M, Cao C, Sun Q, Guo Z, Liu L, Wu D (2020) UBE2T-regulated H2AX monoubiquitination induces hepatocellular carcinoma radioresistance by facilitating CHK1 activation. J Exp Clin Cancer Res 39(1):1–18CrossRef
go back to reference Tan Z (2019) Recent advances in the surgical treatment of advanced gastric cancer: a review. Med Sci Monitor 25:3537CrossRef Tan Z (2019) Recent advances in the surgical treatment of advanced gastric cancer: a review. Med Sci Monitor 25:3537CrossRef
go back to reference Tao N-N, Zhang Z-Z, Ren J-H, Zhang J, Zhou Y-J, Wong VKW, Law BYK, Cheng S-T, Zhou H-Z, Chen W-X (2020) Overexpression of ubiquitin-conjugating enzyme E2 L3 in hepatocellular carcinoma potentiates apoptosis evasion by inhibiting the GSK3β/p65 pathway. Cancer Lett 481:1–14CrossRefPubMed Tao N-N, Zhang Z-Z, Ren J-H, Zhang J, Zhou Y-J, Wong VKW, Law BYK, Cheng S-T, Zhou H-Z, Chen W-X (2020) Overexpression of ubiquitin-conjugating enzyme E2 L3 in hepatocellular carcinoma potentiates apoptosis evasion by inhibiting the GSK3β/p65 pathway. Cancer Lett 481:1–14CrossRefPubMed
go back to reference Wang S, Xian J, Li L, Jiang Y, Liu Y, Cai L, Hoffman RM, Jia L, Zhao H, Zhang Y (2020) NEDD8-conjugating enzyme UBC12 as a novel therapeutic target in esophageal squamous cell carcinoma. Signal Transduct Target Ther 5(1):123CrossRefPubMedPubMedCentral Wang S, Xian J, Li L, Jiang Y, Liu Y, Cai L, Hoffman RM, Jia L, Zhao H, Zhang Y (2020) NEDD8-conjugating enzyme UBC12 as a novel therapeutic target in esophageal squamous cell carcinoma. Signal Transduct Target Ther 5(1):123CrossRefPubMedPubMedCentral
go back to reference Wang T, Jin C, Yang P, Chen Z, Ji J, Sun Q, Yang S, Feng Y, Tang J, Sun Y (2023) UBE2J1 inhibits colorectal cancer progression by promoting ubiquitination and degradation of RPS3. Oncogene 42(9):651–664CrossRefPubMed Wang T, Jin C, Yang P, Chen Z, Ji J, Sun Q, Yang S, Feng Y, Tang J, Sun Y (2023) UBE2J1 inhibits colorectal cancer progression by promoting ubiquitination and degradation of RPS3. Oncogene 42(9):651–664CrossRefPubMed
go back to reference Weinberg J, Whitcomb E, Bohm A, Chekkilla UK, Taylor A (2024) The E3 ligase SMURF1 stabilizes p27 via UbcH7 catalyzed K29-linked ubiquitin chains to promote cell migration SMURF1-UbcH7 K29 ubiquitination of p27 and cell migration. J Biol Chem Weinberg J, Whitcomb E, Bohm A, Chekkilla UK, Taylor A (2024) The E3 ligase SMURF1 stabilizes p27 via UbcH7 catalyzed K29-linked ubiquitin chains to promote cell migration SMURF1-UbcH7 K29 ubiquitination of p27 and cell migration. J Biol Chem
go back to reference Welsh KA, Bolhuis DL, Nederstigt AE, Boyer J, Temple BR, Bonacci T, Gu L, Ordureau A, Harper JW, Steimel JP (2022) Functional conservation and divergence of the helix-turn-helix motif of E2 ubiquitin-conjugating enzymes. EMBO J 41(3):e108823CrossRefPubMed Welsh KA, Bolhuis DL, Nederstigt AE, Boyer J, Temple BR, Bonacci T, Gu L, Ordureau A, Harper JW, Steimel JP (2022) Functional conservation and divergence of the helix-turn-helix motif of E2 ubiquitin-conjugating enzymes. EMBO J 41(3):e108823CrossRefPubMed
go back to reference Xu N, Cui Y, Shi H, Guo G, Sun F, Jian T, Rao H (2022) UBE2T/STAT3 signaling promotes the proliferation and tumorigenesis in retinoblastoma. Invest Ophthalmol vis Sci 63(9):20–20CrossRefPubMedPubMedCentral Xu N, Cui Y, Shi H, Guo G, Sun F, Jian T, Rao H (2022) UBE2T/STAT3 signaling promotes the proliferation and tumorigenesis in retinoblastoma. Invest Ophthalmol vis Sci 63(9):20–20CrossRefPubMedPubMedCentral
go back to reference Yi SA, Kim GW, Yoo J, Han J-W, Kwon SH (2020a) HP1γ sensitizes cervical cancer cells to cisplatin through the suppression of UBE2L3. Int J Mol Sci 21(17):5976CrossRefPubMedPubMedCentral Yi SA, Kim GW, Yoo J, Han J-W, Kwon SH (2020a) HP1γ sensitizes cervical cancer cells to cisplatin through the suppression of UBE2L3. Int J Mol Sci 21(17):5976CrossRefPubMedPubMedCentral
go back to reference Yi SA, Lee DH, Kim GW, Ryu H-W, Park JW, Lee J, Han J, Park JH, Oh H, Lee J (2020b) HPV-mediated nuclear export of HP1γ drives cervical tumorigenesis by downregulation of p53. Cell Death Differ 27(9):2537–2551CrossRefPubMedPubMedCentral Yi SA, Lee DH, Kim GW, Ryu H-W, Park JW, Lee J, Han J, Park JH, Oh H, Lee J (2020b) HPV-mediated nuclear export of HP1γ drives cervical tumorigenesis by downregulation of p53. Cell Death Differ 27(9):2537–2551CrossRefPubMedPubMedCentral
go back to reference Yonemura Y, Canbay E, Li Y, Coccolini F, Glehen O, Sugarbaker P, Morris D, Moran B, Gonzaletz-Moreno S, Deraco M (2016) A comprehensive treatment for peritoneal metastases from gastric cancer with curative intent. Eur J Surg Oncol 42(8):1123–1131CrossRefPubMed Yonemura Y, Canbay E, Li Y, Coccolini F, Glehen O, Sugarbaker P, Morris D, Moran B, Gonzaletz-Moreno S, Deraco M (2016) A comprehensive treatment for peritoneal metastases from gastric cancer with curative intent. Eur J Surg Oncol 42(8):1123–1131CrossRefPubMed
go back to reference Yu Z, Jiang X, Qin L, Deng H, Wang J, Ren W, Li H, Zhao L, Liu H, Yan H (2021) A novel UBE2T inhibitor suppresses Wnt/β-catenin signaling hyperactivation and gastric cancer progression by blocking RACK1 ubiquitination. Oncogene 40(5):1027–1042CrossRefPubMed Yu Z, Jiang X, Qin L, Deng H, Wang J, Ren W, Li H, Zhao L, Liu H, Yan H (2021) A novel UBE2T inhibitor suppresses Wnt/β-catenin signaling hyperactivation and gastric cancer progression by blocking RACK1 ubiquitination. Oncogene 40(5):1027–1042CrossRefPubMed
go back to reference Zeng Z, Sun Q-Q, Zhang W, Wen Q-W, Wang T-H, Qin W, Xiao D-M, Zhang Z, Huang H, Mo Y-J (2021) Assessment of genetic polymorphisms within nuclear factor-κB signaling pathway genes in rheumatoid arthritis: evidence for replication and genetic interaction. Int Immunopharmacol 100:108089CrossRefPubMed Zeng Z, Sun Q-Q, Zhang W, Wen Q-W, Wang T-H, Qin W, Xiao D-M, Zhang Z, Huang H, Mo Y-J (2021) Assessment of genetic polymorphisms within nuclear factor-κB signaling pathway genes in rheumatoid arthritis: evidence for replication and genetic interaction. Int Immunopharmacol 100:108089CrossRefPubMed
go back to reference Zhang S, You X, Zheng Y, Shen Y, Xiong X, Sun Y (2023) The UBE2C/CDH1/DEPTOR axis is an oncogene and tumor suppressor cascade in lung cancer cells. J Clin Investig 133(4) Zhang S, You X, Zheng Y, Shen Y, Xiong X, Sun Y (2023) The UBE2C/CDH1/DEPTOR axis is an oncogene and tumor suppressor cascade in lung cancer cells. J Clin Investig 133(4)
go back to reference Zheng Y-C, Guo Y-J, Wang B, Wang C, Mamun M, Gao Y, Liu H-M (2021) Targeting neddylation E2s: a novel therapeutic strategy in cancer. J Hematol Oncol 14:1–13CrossRef Zheng Y-C, Guo Y-J, Wang B, Wang C, Mamun M, Gao Y, Liu H-M (2021) Targeting neddylation E2s: a novel therapeutic strategy in cancer. J Hematol Oncol 14:1–13CrossRef
go back to reference Zhou W, Xu J, Li H, Xu M, Chen ZJ, Wei W, Pan Z, Sun Y (2017) Neddylation E2 UBE2F promotes the survival of lung cancer cells by activating CRL5 to degrade NOXA via the K11 linkage. Clin Cancer Res 23(4):1104–1116CrossRefPubMed Zhou W, Xu J, Li H, Xu M, Chen ZJ, Wei W, Pan Z, Sun Y (2017) Neddylation E2 UBE2F promotes the survival of lung cancer cells by activating CRL5 to degrade NOXA via the K11 linkage. Clin Cancer Res 23(4):1104–1116CrossRefPubMed
go back to reference Zhou L, Ren JH, Cheng ST, Xu HM, Chen WX, Chen DP, Wong VKW, Law BYK, Liu Y, Cai XF (2019) A functional variant in ubiquitin conjugating enzyme E2 L3 contributes to hepatitis B virus infection and maintains covalently closed circular DNA stability by inducing degradation of apolipoprotein B mRNA editing enzyme catalytic subunit 3A. Hepatology 69(5):1885–1902CrossRefPubMed Zhou L, Ren JH, Cheng ST, Xu HM, Chen WX, Chen DP, Wong VKW, Law BYK, Liu Y, Cai XF (2019) A functional variant in ubiquitin conjugating enzyme E2 L3 contributes to hepatitis B virus infection and maintains covalently closed circular DNA stability by inducing degradation of apolipoprotein B mRNA editing enzyme catalytic subunit 3A. Hepatology 69(5):1885–1902CrossRefPubMed
go back to reference Zhu J, Ao H, Liu M, Cao K, Ma J (2021) UBE2T promotes autophagy via the p53/AMPK/mTOR signaling pathway in lung adenocarcinoma. J Transl Med 19:1–17CrossRef Zhu J, Ao H, Liu M, Cao K, Ma J (2021) UBE2T promotes autophagy via the p53/AMPK/mTOR signaling pathway in lung adenocarcinoma. J Transl Med 19:1–17CrossRef
Metadata
Title
UBE2L3 expression in human gastric cancer and its clinical significance
Authors
Xiaoxia Zhang
Yujie Wei
Fanqi Wu
Mei Li
Cong Han
Chengdong Huo
Zhi Li
Futian Tang
Wenting He
Yang Zhao
Yumin Li
Publication date
01-04-2024
Publisher
Springer Berlin Heidelberg
Published in
Journal of Cancer Research and Clinical Oncology / Issue 4/2024
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-024-05669-7

Other articles of this Issue 4/2024

Journal of Cancer Research and Clinical Oncology 4/2024 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.